Andere Kunden interessierten sich auch für
![Assessment of the Effect of Copper Complex on Autophagy in TNBC cells]( "Assessment of the Effect of Copper Complex on Autophagy in TNBC cells")
Assessment of the Effect of Copper Complex on Autophagy in TNBC cells40,99 €![Role of Transient Receptor Potential Channels in Pain Modulation]( "Role of Transient Receptor Potential Channels in Pain Modulation")
Role of Transient Receptor Potential Channels in Pain Modulation24,99 €![New Antimalarial Combinations for Chloroquine Resistant Malaria]( "New Antimalarial Combinations for Chloroquine Resistant Malaria")
New Antimalarial Combinations for Chloroquine Resistant Malaria51,99 €![Genetics]( "Genetics")
Genetics46,99 €![Paroxetine and multiple myeloma]( "Paroxetine and multiple myeloma")
Paroxetine and multiple myeloma27,99 €![Cell Cycle and Cell Division]( "Cell Cycle and Cell Division")
Cell Cycle and Cell Division26,99 €![Chemical Profiling and Cytotoxic study of Hexagonia tenuis (Hook.)Fr.,]( "Chemical Profiling and Cytotoxic study of Hexagonia tenuis (Hook.)Fr.,")
Chemical Profiling and Cytotoxic study of Hexagonia tenuis (Hook.)Fr.,36,99 €
Doxorubicin is regarded as the most therapeutic active agent available for triple-negative breast cancer (TNBC) treatment. However, the development of drug resistance and toxicity limits its effectiveness. Thus, developing novel strategies for TNBC treatment remains a significant challenge and doxorubicin-based combinations either by metal complexes (Copper I nicotinate complex) or with autophagy modulators could provide novel strategies and alternative strategies contributed to cancer cell death pathways, autophagy and apoptosis.